Of the classical antidiabetic agents, a meta-analysis showed that pooled data of sodium-glucose transporter-2 (SGLT2) inhibitors empagliflozin and dapagliflozin indicate a protective effect against new-onset T2DM (62). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.